161 related articles for article (PubMed ID: 1835223)
1. Intravenous or intramuscular teicoplanin once daily for skin and soft-tissue infections.
Edelstein HE; Oster SE; Chirurgi VA; Karp RA; Cassano KB; McCabe RE
DICP; 1991 Sep; 25(9):914-8. PubMed ID: 1835223
[TBL] [Abstract][Full Text] [Related]
2. Teicoplanin in the treatment of skin and soft tissue infections.
Turpin PJ; Taylor GP; Logan MN; Wood MJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():117-22. PubMed ID: 2965123
[TBL] [Abstract][Full Text] [Related]
3. Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.
Lang E; Földes M; Marghescu S
Infection; 1991; 19(3):190-4. PubMed ID: 1832418
[TBL] [Abstract][Full Text] [Related]
4. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison trial of teicoplanin i.v., teicoplanin i.m., and cefazolin therapy for skin and soft tissue infections caused by gram-positive bacteria.
Chirurgi VA; Edelstein H; Oster SE; Karp R; Cassano KB; Aiken S; McCabe RE
South Med J; 1994 Sep; 87(9):875-80. PubMed ID: 8091249
[TBL] [Abstract][Full Text] [Related]
6. Teicoplanin, a new antibiotic effective against gram-positive bacterial infections of the skin and soft tissues.
Bochud-Gabellon I; Regamey C
Dermatologica; 1988; 176(1):29-38. PubMed ID: 2962889
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin in the treatment of infection caused by gram-positive organisms.
Williams AH; Grüneberg RN; Webster A; Ridgway GL
J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091
[TBL] [Abstract][Full Text] [Related]
8. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria.
Lewis P; Garaud JJ; Parenti F
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():61-7. PubMed ID: 2965133
[TBL] [Abstract][Full Text] [Related]
9. An open study of teicoplanin in the treatment of gram-positive infections.
Nathwani D; Reid TM; Gould IM; Golder D; Smith CC; Douglas JG
J Chemother; 1991 Oct; 3(5):315-20. PubMed ID: 1839742
[TBL] [Abstract][Full Text] [Related]
10. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.
Galanakis N; Giamarellou H; Vlachogiannis N; Dendrinos C; Daikos GK
Eur J Clin Microbiol Infect Dis; 1988 Apr; 7(2):130-4. PubMed ID: 2968907
[TBL] [Abstract][Full Text] [Related]
11. Teicoplanin--domiciliary use in surgical infections.
Rubinstein E
Eur J Surg Suppl; 1992; (567):27-9. PubMed ID: 1381638
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci.
Harding I; Garaud JJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():93-103. PubMed ID: 2965137
[TBL] [Abstract][Full Text] [Related]
13. Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections.
Sexton DJ; Wlodaver CG; Tobey LE; Yangco BG; Graziani AL; MacGregor RR
Chemotherapy; 1991; 37 Suppl 2():26-30. PubMed ID: 1879184
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of teicoplanin.
Stille W; Sietzen W; Dieterich HA; Fell JJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():69-79. PubMed ID: 2965134
[TBL] [Abstract][Full Text] [Related]
15. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
[TBL] [Abstract][Full Text] [Related]
17. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.
Pauluzzi S; Del Favero A; Menichetti F; Baratta E; Moretti VM; Di Filippo P; Pasticci MB; Guerciolini R; Patoia L; Frongillo RF
J Antimicrob Chemother; 1987 Sep; 20(3):431-8. PubMed ID: 2960643
[TBL] [Abstract][Full Text] [Related]
18. Treatment of bone and soft tissue infections with teicoplanin.
Marone P; Concia E; Andreoni M; Suter F; Cruciani M
J Antimicrob Chemother; 1990 Mar; 25(3):435-9. PubMed ID: 2140111
[TBL] [Abstract][Full Text] [Related]
19. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
Wilcox M; Nathwani D; Dryden M
J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
[TBL] [Abstract][Full Text] [Related]
20. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
de Lalla F; Santoro D; Rinaldi E; Suter F; Cruciani M; Guaglianone MH; Rizzardini G; Pellegata G
J Antimicrob Chemother; 1989 Jan; 23(1):131-42. PubMed ID: 2526109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
